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Abstract
Nontuberculous mycobacteria (NTM) are a heterogeneous group of microorganisms 
other than Mycobacterium tuberculosis (M. tuberculosis) complex and Mycobacterium leprae. 
NTM infections have increased globally and are now considered an emerging infection 
as they are often encountered in developed countries. NTMs require extended treat-
ment adding considerably to the economic burden. The increasing number of patients 
with immunocompromised disorders, increasing usage of immunosuppressive agents, 
general awareness of the NTM diseases due to the advancement in molecular diagnostic 
techniques and aging of the population increase the prevalence rate of NTM infections. 
However, several barriers such as the requirement of better diagnostic techniques, settled 
treatment guidelines, clinician awareness and knowledge of pathogenesis are limiting and 
NTM infections are often not treated promptly. Etiology and epidemiology of NTM infec-
tions [Mmycobacterium avium complex (slowly growing mycobacteria, SGM) and rapidly 
growing mycobacteria (RGM)] are discussed in this chapter. Clinical features, diagnosis 
and currently available treatment guidelines for these infections in skin, eye and lung are 
summarized. Suggestions for future research directions are suggested particularly for the 
better understanding of host-pathogen crosstalk and new therapeutic strategies.
Keywords: nontuberculous mycobacteria, rapidly growing mycobacteria, slowly 
growing mycobacteria, biofilms, eye, lung, skin
1. Introduction
1.1. Etiology, epidemiology and possible sources of NTM infections
The NTM group of mycobacteria is nonmotile aerobic bacilli, acid-fast (AF) staining organ-
isms [1]. The lipid-enriched hydrophobic cell well is usually thicker than other bacteria 
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characterized by tolerance to many disinfectants, heavy metals and antibiotics [1, 2]. They 
are frequently found in the environment such as soil and water. They readily form biofilms, 
which contributes to their resistance against a variety of antibiotics [3] as well as high tem-
peratures and a wide range of pH [4]. Environmental recovery of these NTM is the same when 
they do in similar culture techniques in different geographical regions [5]. However, western 
countries are reporting a greater prevalence of NTM infections compared to Tuberculosis (TB) 
than most Asian countries due to very stringent prevention and treatment of tuberculosis [6]. 
Not all the culture-positive samples represent infection and only half of the culture-positive 
patients have active respiratory infections, highlighting that NTM can be silent in presence of 
a normal immune response [7]. Reports suggest that older patients and women have higher 
chances of NTM infections [8]. As an outcome of the Human Immunodeficiency Virus (HIV) 
epidemic, NTM infections are frequently isolated from the blood of HIV patients [9]. In the 
United States, NTM cultures (more than 90%) are from pulmonary disease [10]. According to 
the Infectious Diseases Society of American Emerging Infections Network and Information 
from referral centers report, NTM infections are emerging pathogens, particularly rapidly 
growing mycobacteria (RGM) such as Mycobacterium abscessus (M. abscessus), Mycobacterium 
chelonae (M. chelonae) and Mycobacterium fortuitum (M. fortuitum) [11]. The prevalence and 
trend of NTM pulmonary infections are increasing, particularly in Florida and New York, 
calculated from United States census data from 1998 through 2005 [12]. NTM are the most 
common pathogens after cosmetic surgeries such as tattooing and Laser in situ keratomileusis 
(LASIK) [13, 14]. Increasing reports of NTM infections are expected in eye, skin, and lung 
due to the popularity of LASIK, increasing population of immunocompromised patients and 
older population. NTM pulmonary infections are found in the areas with heavy population, 
indicating that urban water supply increases individual’s exposures to NTM [15]. NTM infec-
tions are frequently associated with farmers in Japan, suggesting that soil is the main source of 
infection there [16]. For NTM lung infections, aerosolization of droplets by bathroom showers 
may be another route of infection [17]. Water is considered to be a normal habitat for NTM and 
households with low water heater temperature are found to correlate with NTM infections 
[18]. Hospital water supply is considered to be vital in controlling NTM infections and dialysis 
solutions contaminations have led to the NTM outbreaks [19–21]. Contaminated tap water and 
increased demand of cosmetic surgeries in freestanding health centers that cannot be reviewed 
frequently by the infectious diseases control center are other concerns for NTM outbreaks [22].
1.2. Runyon’s classification
Runyon classified NTM into four groups, I–IV [23–25]. Group I, photochromogens, which usu-
ally grow slowly about 2–4 weeks and change to yellow with light exposure. Group II, scotochro-
mogens, consist mainly of M. gordonae and appear as yellow colonies at 2–4 weeks in agar plates 
when cultured in the dark. Group III are nonphotochromogens, slowly growing mycobacteria, 
which grow slowly over 2–4 weeks. The rapid growers, group IV NTMs are the most patho-
genic and important for human disease. They are divided into three subgroups: M. fortuitum, M. 
chelonae/abscessus, and M. smegmatis. According to the literature, they are susceptible to various 
antibiotics such as sulfonamide, polymyxin B, and the third- and fourth-generation fluoroqui-
nolones [25]. Group III organisms are lung pathogens and Group IV organisms are the most 
important and prevalent strains for the eye, lung cutaneous and subcutaneous infections [25].
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1.3. Laboratory diagnosis and barriers
Culture technique is the typical standard method for the identification of suspicious NTM. The 
organisms must be cultured on specific media such as AF smear, Lowenstein-Jensen (LJ) 
media, Middlebrook media and MacConkey agar since it cannot be differentiated by Gram-
stain [26]. The organisms must be cultured in both liquid medium for growing a large amount 
of organism for other tests and solid medium to observe colony morphology and characteristic 
[27]. Moreover, the organisms should be further identified into subspecies level for different 
appropriate antimicrobial therapy. Subspecies level can be achieved by using gene sequenc-
ing, high-performance liquid chromatography (HPLC), and molecular-based methods [28]. 
HPLC is a fast, reliable method for identifying NTM. However, HPLC has limitations: it cannot 
separate between M. abscessus and M. fortuitum/M. chelonae [29]. Molecular probes, acridinium 
ester-labeled DNA probes have been made commercially and approved by the U.S. Food and 
Drug Administration (FDA) for the rapid identification of NTM [30]. MicroSeq 500 16S rDNA 
Bacterial Sequencing Kit (PE Applied Biosystems, Foster City, CA) has been developed to 
identify the NTM strain [31]. However, misdiagnoses frequently occur due to the low fre-
quency of these infections, coupled with a lack of diagnostic experience for NTM infections, 
as well as confusing morphological features in stained smears [28]. Misdiagnosis can be com-
plicated by incorrectly correlating laboratory results by physicians [32]. Misdiagnosis of NTM 
infections can lead to fatal incidents and NTM often exhibit the microbiological features of 
Corynebacterium species with long filamentous beaded appearances [33, 34]. NTM microscopic 
features are also similar to Nocardia species [35]. Therefore, clinicians are taking note of these 
emerging infections for prompt and focused diagnosis to initiate effective treatment.
Figure 1. Bar graph showing the incidences of NTM in Singapore (2007–2017). Other NTM consists of M. szulgai, M. terrae 
complex, M. haemophilum, M. intracellulare, M. marinum, M. mucogenicum, M. neoaurum, M. scrofulaceum, M. simiae, M. 
mageritense, M. wolinskyi, M. asiaticum, M. celatum, M. chimaera, M. duvalli, M. cookii, M. cosmeticum, M. chlorophenolicum, 
M. genavense, M. kubicae, M. lentiflavum, M. mantenii, M. obuense, M. stomatepiae, M. triplex and M. xenopi.
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1.4. NTM incidence in Singapore (2007–2017)
The incidences of NTM cases in Singapore are rising in the recent years, about 3000 cases per 
year [36] (Figure 1). Among NTM, M. abscessus is responsible for most of the identified NTM 
cases in Singapore, followed by M. fortuitum, M. avium complex and M. chelonae (Figure 1).
2. NTM cutaneous and subcutaneous infections
2.1. Mycobacterium abscessus
M. abscessus, a fast-growing NTM, is commonly found in water drainage systems and sew-
age. It is a subset of the M. chelonae complex and it is vital to segregate from the M. chelonae 
complex due to the dissimilar antibacterial treatment option. It is well known that the clinical 
success of M. abscessus depends on the host’s immune defense [37]. It was reported that M. 
abscessus caused posttransplant infection in cystic fibrosis (CF) patients in spite of having 
antimicrobial treatment [38]. They are responsible for the major causes of skin and soft tissue 
infections in the literatures [39] and they are the most common cause of identified NTM infec-
tions in Singapore (Figure 1). The path of entries for this organism is direct inoculation such 
as skin piercing or injury [40] or secondary involvement from disseminated infection [41]. The 
most likely source of infection is from tap water. Water and soil are the natural habitats for M. 
abscessus [4, 42]. M. abscessus outbreaks have been reported in clinic and hospitals worldwide 
and the contaminated instruments or disinfectants are the major sources of the outbreaks [41].
2.1.1. Clinical features and causes of M. abscessus cutaneous and subcutaneous infections
M. abscessus infected skin usually presents with painful, swollen and tender to the touch, 
accompanying with pus-filled vesicles. Nonspecific symptoms of infections may be present 
such as fever with chills, muscle aches, and malaise. Causes of M. abscessus infections include 
posttraumatic wound infections [20], postinjection wound infections [20] and surgical wound 
infections (mammoplasties, plastic surgeries, and heart surgeries) [20].
2.2. Mycobacterium fortuitum
M. fortuitum is a principal cause of cutaneous and subcutaneous infections associated with 
catheters [43, 44] as well as post surgical wound infections [45]. The route of entry for M. 
fortuitum is direct inoculation from contaminated water through the lesions.
2.2.1. Clinical features and causes of M. fortuitum cutaneous and subcutaneous infections
Small, erythematous papules are frequent signs of the early stages of infection and large, 
fluctuant, painful violaceous boils and ulcerations are signs for late stage infections [45, 46]. 
They can be caused by mesotherapy and present with indurated, erythematous and viola-
ceous papules with 3–20 numbers, the diameter ranging from 0.5 to 6 cm, accompanied by 
inguinal or axillary lymphadenopathy [47]. M. fortuitum can also be recovered from blood and 
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purulent discharge from patients with venous catheters [43, 44] and is the cause of post surgi-
cal wound infections such as liver transplant patients, electromyography and punch biopsy 
procedures [44, 48, 49].
2.3. Mycobacterium chelonae
M. chelonae infections are usually associated with immunocompromised hosts such as HIV 
patients [50]. It can be seen in postsurgical wounds and can disseminate hematogenoulsy to 
cause sepsis. Contaminated water is the most common source of infection and the route of 
entry is direct inoculation.
2.3.1. Clinical features and causes of M. chelonae cutaneous and subcutaneous infections
Circumscribed, red, infiltrative plaques, umbilicated papules, and pustules on the upper part 
of the body and face are features of M. chelonae skin lesions and frequently accompanied 
by cervical lymphadenopathy [51]. Immunocompromised patients, HIV/AIDS patients often 
contract M. chelonae infections [50]. Kidney transplant patients, liver transplant patients, tat-
tooing, kidney dialysis patients and peritoneal dialysis patients are also frequently associated 
with M. chelonae infections [13, 52, 53]. Reports suggest that immunosuppressive drugs such 
as prednisolone, methotrexate, and adalimumab [54, 55], and autoimmune diseases such 
as Cushing’s syndrome and rheumatoid arthritis are often associated with M. chelonae skin 
infections [55, 56].
2.4. NTM cutaneous and subcutaneous infections
The correct choice of antimicrobial agent, anatomic locations of the lesions, intracellular 
uptake and target binding are essential for the management of NTM cutaneous and subcuta-
neous infections. Moreover, an appropriate route of drug administration (oral, intravenous 
or intramuscular), acceptable and effective drug concentration is required for the treatment 
plan. Drug resistance mechanisms for rapidly growing mycobacteria (RGM) involving erm 
gene must be considered due to the prolonged treatment period. Therefore, it is critical to 
differentiate and identify rapidly growing mycobacterial at the subspecies level [25, 57]. The 
decision of choosing either surgical debridement in combination with mono or multidrug 
therapy, or only mono or multidrug therapy depends on the anatomical location and sever-
ity of the lesion, patient’s immune status with presence of underlying pathology (Table 1) 
and the Minimum Inhibitory Concentration (MIC) breakpoints from the microbiology lab 
(Tables 2 and 3).
2.4.1. M. abscessus cutaneous and subcutaneous infections
Macrolides are the gold standard treatment for M. abscessus infections. They exhibit bacteri-
cidal actions against M. abscessus when the lesion has a small population of bacteria. Reports 
suggest that azithromycin and clarithromycin are the gold standard for treating M. abscessus 
infections in disseminated cases; however, there are reports suggesting the evolution of resis-
tance against these drugs in prolonged monotherapy [11, 58]. Tigecycline, a new antibiotic, 
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may be another choice for M. abscessus infections [59]. Amikacin is known to be the treatment 
of choice since it is active against all the subspecies of RGM and imipenem or cefoxitin can be 
added to overcome treatment failures [11, 58]. Surgical debridement plays a role in the better 
treatment outcomes for M. abscessus infections [60].
2.4.2. M. fortuitum cutaneous and subcutaneous infections
M. fortuitum infections are chronic in nature and in vitro drug susceptibility tests are required 
for a guidance of choosing the correct antibiotics. Usually, M. fortuitum are sensitive to several 
oral antimicrobials such as quinolones, sulfonamides, and macrolides [61, 62]. Amikacin is 
the treatment of choice for M. fortuitum with 100% efficacy, while sulfonamide and imipenem/
Susceptible Intermediate Resistant
Doxycycline/minocycline ≤1 2–4 ≥8
Imipenem/meropenem ≤4 8–16 ≥32
TMP/SMX ≤2/38 – ≥4/76
Tobramycin ≤2 4 ≥8
Moxifloxacin ≤1 2 ≥4
Table 2. MIC breakpoints for RGM [112, 113].
RGM Disease pattern Antimicrobial agents
M. fortuitum 2–8 week duration with 
significant signs and 
symptoms
Combination of amikacin, quinolones or tobramycin (imipenem)
After IV treatment or disease 
with reduced signs and 
symptoms
Linezolid
Doxycycline
Clarithromycin
Trimethoprim/sulfamethoxazole
M. abscessus 2–8 week duration with 
significant signs and 
symptoms
Combination of clarithromycin, amikacin, cefoxitin (imipenem) or 
tigecycline
After IV treatment or disease 
with reduced signs and 
symptoms
Linezolid
M. chelonae 2–8 week duration with 
significant signs and 
symptoms
Combination of clarithromycin, linezolid (tobramycin, imipenem, 
tigecycline or oral drug)
After IV treatment or disease 
with reduced signs and 
symptoms
Gatifloxacin
Doxycycline
Linezolid
Clarithromycin
Table 1. Clinicians’ choice of antibiotic regimes for different RGM infections [112].
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cilastatin also account for 100%, clarithromycin stands for 80% and linezolid and doxycy-
cline accounts for 50% [63]. Due to rising chances of bacterial resistance to macrolide due 
to the inducible erm gene, clarithromycin uses should be carefully assessed and monitored 
[52, 63, 64]. Linezolid is another good candidate for M. fortuitum in in vitro; however, more 
human clinical studies would be warranted for the future use [65]. The minimum 4 months 
duration of the combination of two drugs is required for severe or critical M. fortuitum cutane-
ous and subcutaneous infections. Reports are suggested that surgical debridement or surgical 
drainage is indicated for the better antimicrobial treatment therapy or helping to cure the M. 
fortuitum infections particularly in extensive disease and abscesses [66]. M. fortuitum usually 
possess the erm gene, which is inducible to promote resistance to clarithromycin. There was a 
report showing that sensitivity testing of M. fortuitum isolates showed trailing MICs against 
macrolides [67]. However, the relevance of the erm gene in M. fortuitum and clarithromycin 
treatment remains to be determined in clinical management.
2.4.3. M. chelonae cutaneous and subcutaneous infections
Clofazimine is shown to be effective and the addition of sub MIC concentration of amikacin 
synergies with clofazimine against RGM including M. chelonae [68]. Tobramycin has been 
suggested to be a better treatment option than amikacin [69]. However, M. chelonae isolates 
showed resistant to cefoxitin and imipenem is the alternative option. There is MIC susceptibil-
ity of clarithromycin (100%), tobramycin (100%), linezolid (90%), imipenem (60%), amikacin 
(50%), doxycycline (25%), clofazimine (25%) and ciprofloxacin (20%) [63]. However, M. chelo­
nae is susceptible only to clarithromycin, tobramycin, and tigecycline [70]. Monotherapy is not 
advisable for M. chelonae infections due to its facility to acquire drug resistance and combina-
tion treatment is advised [71]. Excision and treatment is still the optimal treatment step in 
combination with antibiotics in treating M. chelonae cutaneous and subcutaneous infections 
[66]. Treatment guidelines are not yet reported; however, current guidelines recommend 
using antimicrobial susceptibility tests to predict therapeutic efficacy.
3. NTM eye infections
3.1. Clinical features and causes of NTM eye infections
The most prevalent NTM strains causing eye infections are M. fortuitum and M. chelonae 
[72, 73]. Keratitis is standing as the most common real situation accounting for 69% of ocular 
NTM infections (Table 4).
RGM Drug Reporting
M. fortuitum Clarithromycin Trailing endpoints, report as resistant
Imipenem New breakpoint (8–16 μg/ml) for reproducible MIC
M. abscessus Amikacin If MIC is more than 64 μg/ml, need to repeat/confirm
M. chelonae Tobramycin If MIC is more than 4 μg/ml, need to repeat/ confirm
Table 3. Reporting MICs of RGM [112].
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Different types of ocular NTM infection Percentage
1. Ocular surface infections
 a. Keratitis 69
 b. Scleritis 4.3
 c. Conjunctivitis 0.7
2. Periocular and adnexal infections 13.3
3. Intraocular infections and uveitis 12.6
Table 4. Different types of ocular infection caused by NTM [14].
Late presentation of symptoms and diagnosis was reported in NTM keratitis [74]. Pain, 
decreased vision, and photophobia were present in gradual increasing patterns in the course 
of NTM keratitis [75]. The multifocal or single lesion surrounded by radiating corneal infil-
trates, ‘cracked windshield’ appearance, was reported [74, 76, 77]. Infiltrates had irregular 
margins, mimicking fungal keratitis [78]. Hypopyon is present in untreated or poorly treated 
cases [74]. There have been reports of infectious crystalline keratopathy, intrastromal opacity 
and minimal inflammation in some cases of NTM keratitis leading to a misleading diagnosis 
of herpetic keratitis [79, 80] (Table 5).
The most common association of NTM keratitis is LASIK (47.6%), followed by trauma (14.8%), 
foreign body (17.6%), implants (17.3%) and contact lens (6.4%) [14]. LASIK is the most popular 
refractive corrective surgery implemented worldwide since it offers less stromal scarring and 
rapid recovery of visual acuity. The symptoms for post-LASIK mycobacterial keratitis are less 
severe than other causes [26]. The time frame of 3 to 14 weeks duration is reported to present 
post-LASIK NTM keratitis. Some cases of post-LASIK mycobacterial keratitis present within 
10 days post surgery [26, 81]. The most probable route of entry for post-LASIK NTM keratitis 
is during the surgery. Corneal infiltrates are within the lamellar flap or interface presenting 
with either single white lesion or multiple white granular appearances. Anterior extension 
of corneal infiltrates is common to form a corneal ulceration. Late diagnosis or treatment can 
result in the posterior extension into the corneal stroma. The anterior chamber is usually silent 
or has the mild inflammatory reaction [26, 82].
3.2. Treatment of NTM eye infections
Management of NTM keratitis is challenging due to its rarity, potential to acquire antibiotic 
resistance, natural resistance to a variety of commercially available antibiotics and delayed 
response to antibiotics. Identification of NTM keratitis can be delayed and one report revealed 
that the time to identification was delayed for 4 months due to slow growth of the organism 
[83]. Drug sensitivity tests need to be carried out using a prolonged incubation time, resulting 
in the delayed treatment of NTM eye infections. Moreover, there are several reports showing 
that a wide range of antibiotic sensitivities exists in different isolates [84]. Consequently, a 
combination of two or three drugs helps to prevent acquired antibiotic resistance in long-term 
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management and clarithromycin, amikacin, and fourth generation fluoroquinolones are men-
tioned [85]. Topical delivery is the most used method followed by the combination of topical 
and systemic administration [14]. Amikacin is known to be the treatment of choice for NTM 
keratitis, however, there have been reports showing corneal toxicity toward the long-term 
usage of amikacin in high concentration [86]. According to the systemic review, amikacin 
was given alone in the majority of NTM keratitis cases, followed by amikacin and macro-
lide (Table 6) [14]. Fluoroquinolones, particularly fourth-generation fluoroquinolones, have 
been accepted as effective for eye infections [3, 86]. Fourth generation fluoroquinolones offer 
noteworthy benefits over the older generations because of their superior bactericidal activity, 
decreased risk for resistance and higher corneal concentrations. In contrast, one report sug-
gested that the majority of nontuberculous mycobacteria are resistant to second-generation 
fluoroquinolones, highlighting the better efficacy properties of fourth generation fluoroq-
uinolones [87].
Recent reports suggest a strong synergism between amikacin and fourth generation fluoro-
quinolone, gatifloxacin, in treating nontuberculous mycobacteria in in vitro and in vivo mouse 
keratitis model [88]. Moreover, it was reported that the NTM habitat in a keratitis infection 
is in the biofilm mode (Figure 2) hindering antibiotic penetration and adding DNase to the 
antibiotic may make a more effective treatment [88]. Surgical debridement can help to facilitate 
penetration and lower the bacterial load. Topical steroids are controversial for NTM keratitis 
and one study suggested that a steroid accelerates the infection [89]. Careful follow up of NTM 
Symptoms Signs
Varying degree of pain Multiple lesions or single lesion surrounded by the radiating projections
Photophobia Cracked windshield appearance
Tearing and foreign body sensation Hypopyon
Decreased visual acuity Mild or Silent anterior chamber
Table 5. Signs and symptoms of NTM keratitis.
Different antibiotic regimen Percentage
Amikacin only 29.2
Combination of amikacin and macrolide 14.1
Combination of amikacin and fluoroquinolone 12.5
Combination of amikacin, fluoroquinolone and macrolide 9.4
Combination of fluoroquinolone and macrolide 8.3
Other antibiotics 7.3
Fluoroquinolone only 6.8
Table 6. Different antibiotic regimens for NTM keratitis [14].
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keratitis patients is suggested; if the lesion is in progression, or stromal thinning and symp-
toms persistence continues after 2 days of antibiotics, drug sensitivity should be rechecked for 
an alternative sensitive antimicrobial. However, there is no agreed-upon treatment plan for 
NTM keratitis and more research including evaluation of new treatment plans and an in-depth 
knowledge of NTM keratitis pathogenesis is warranted to treat NTM keratitis effectively.
4. NTM lung infections
4.1. Clinical features and causes of NTM lung infections
NTM lung infections are often due to Mycobacterium avium complex (MAC) and RGM. NTM 
lung disease may be misdiagnosed as Tuberculosis and require weeks or months [90]. The 
clinical diagnosis and treatment remain challenging due to its nonspecific symptoms such as 
low-grade fever, wet chronic cough, weight loss and malaise similar to M. tuberculosis [91]. 
Radiological imaging is a vital test to screen for NTM lung disease. A broad range of radio-
logical patterns such as bronchiectasis, cavitary lesions, nodular lesions and parenchymal 
lesions, have been observed in NTM lung disease [92]. However, two major radiological find-
ings have been listed, fibrocavitary and nodular bronchiectatic forms [93]. The first form is 
similar to pulmonary TB and it usually affects elderly male with underlying pathology of the 
lung. Cavities with increased opacity are usually seen in the upper parts of the lung in the 
fibrocavitary form [94]. Thin-walled cavities without lymph node involvement and atelectasis 
are the common findings in this form [95]. The nodular bronchiectatic form often presents 
Figure 2. Slit lamp photograph showing central haziness in NTM keratitis mouse model. Confocal microscopy 
images showing presence of atypical mycobacterial microcolonies biofilm formation (green color) with abundance of 
extracellular DNA (a major constituent of mycobacterial biofilm matrix in red color) [88].
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with bilateral, small nodules and multilobar bronchiectasis in the lower and middle parts 
of the lung [96]. This disease pattern is associated with elderly nonsmoking women without 
underlying lung diseases [97]. There is a connection between bronchiectasis and NTM lung 
diseases [98]. Because of NTM’s nonspecific symptoms and similar radiological findings as 
M. tuberculosis and other lung pathologies, it is extremely hard to diagnose NTM lung dis-
ease. Risk factors causing NTM lung disease are still poorly understood but immune status 
is vital for NTM lung disease. A study showed that disseminated NTM infection is often 
associated in patients with profound immunosuppression [99]. NTM are important patho-
gens for patients who have undergone or are awaiting lung transplant and cystic fibrosis 
patients [100]. Defects in the crucial elements of the host defense such as interleukin-12 (IL-12) 
and interferon-gamma (IF-γ) increase susceptibility to NTM lung infections [101]. Increasing 
usage of tumor necrosis factor (TNF-α) receptor antagonists usage enhances NTM infections 
[102]. The rate of NTM prevalence in TNF-α receptor antagonists usage is 74/100,000 persons 
per year [103].
4.2. Treatment of NTM lung infections
4.2.1. MAC lung infections
Macrolides are the treatment of choices for MAC lung infections [104]. Rifampin or etham-
butol can be added to macrolide administration for 18–24 months [63]. Rifampin 600 mg/kg, 
ethambutol 25 mg/kg with either azithromycin 500 mg/kg or clarithromycin 1000 mg/kg is 
frequently given as three-times-weekly intermittent therapy for NTM noncavitary lung dis-
ease [63]. It has been suggested that intermittent therapy is more efficient and reduced toxicity 
than daily therapy [105]. A cocktail of rifampin 10 mg/kg/day, ethambutol 15 mg/kg/day with 
either azithromycin 250 mg/kg/day or 1000 mg/kg is given daily for cavitary nodular bronchi-
ectatic NTM lung disease, with a possibility of adding either streptomycin or amikacin in the 
first 2 or 3 months of therapy in severe disease [63].
The addition of moxifloxacin to the standard treatment showed a better response if a standard 
treatment plan fails [106]. Clofazimine has shown that it can be an alternative option to the 
rifampin or in refractory MAC lung infections [107]. The successful treatment of NTM lung 
infections totally relies on the prevention of macrolide-resistant MAC infections with the opti-
mal treatment strategies.
4.2.2. RGM lung infections
The management for RGM lung infections typically depends on drug’s toxicity and drug 
sensitivity tests. Treatment for M. abscessus lung infection is challenging as shown in previ-
ous studies [108]. The recommended guideline for treating RGM lung infection includes a 
combination of treatment which involves two parenteral antibiotics and an oral macrolide for 
a relatively long duration (several months) [63]. The most active and useful parenteral agents 
consist of amikacin 10–15 mg/kg/day, imipenem 500–1000 mg2, cefoxitin 200 mg/kg/day, and 
tigecycline 50 mg/day [108]. Moxifloxacin has been shown as an alternative option for treating 
RGM lung infections [109]. Aggressive parenteral therapy is suggested for initial 4 months 
of treatment accompanied later by a treatment combination of macrolide and linezolid or 
clofazimine or fluoroquinolone for coping with toxicity [108]. Treatment with macrolides for 
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RGM infection should be carefully accessed on the patient’s tolerance and treatment com-
pliance due to the possibility of drug resistance evolved [110]. Surgical resection should be 
considered to combine with chemotherapy in treating RGM lung infections [111].
5. Conclusion
Etiology and epidemiology of NTM infections highlight that NTMs are emerging pathogens, 
warranting more research. Clinical features, barriers in the diagnosis of NTM and a lack of 
more effective treatment strategies were discussed for NTM infections in lung, skin and eye 
system. This overview prompts comments that can be made for NTM infections for future 
research. (1) NTM infections are considered emerging pathogens around the world including 
Singapore. (2) Better understanding of microbial life in real human clinical scenarios is impor-
tant in dealing with the easy biofilm forming NTMs. (3) More research is critically needed 
to fill a huge gap of host-pathogen interactions in NTM infections. (4) A Multidisciplinary 
approach, better diagnostic tools, increase public awareness and standard treatment guide-
lines and new therapeutic research is urgently required.
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